Division of Pediatric Hematology/Oncology, University of California Davis School of Medicine, Sacramento, California, USA.
Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento, California, USA.
Pediatr Blood Cancer. 2021 Jul;68(7):e28998. doi: 10.1002/pbc.28998. Epub 2021 Mar 15.
Ewing sarcoma (EWS) and osteosarcoma (OS) require multidisciplinary treatment. Care at specialized cancer centers (SCC: Children's Oncology Group affiliated and/or National Cancer Institute-designated cancer center) has been found to improve outcomes in patients with leukemia, but studies have not considered location of care and outcomes in EWS and OS patients, an ideal group to evaluate given their specialized multidisciplinary treatment needs.
Patients hospitalized with primary EWS and OS (2000-2014) were identified using the California Cancer Registry linked with hospitalization data. Patients were divided into age groups (0-18, 19-39, ≥40 years), and classified on whether they received all versus part/none of their inpatient treatment at a SCC within 1 year of diagnosis. Multivariable Cox proportional hazards regression identified factors associated with survival.
There were 531 ES and 959 OS patients. Five-year overall survival was better for patients with EWS (all: 63% vs. part/none: 42%) and OS (all: 64% vs. part/none: 47%) who received all of their treatment at a SCC. After adjusting for sociodemographic and clinical factors, receiving all inpatient cancer treatment at a SCC was associated with superior overall survival (EWS HR: 0.49, CI 0.37-0.67; OS HR: 0.78, CI 0.63-0.97).
Our results suggest that treatment for EWS and OS at a SCC is associated with significantly improved survival even after adjustment for known prognostic factors. The superior survival among those treated at SCCs may be due to having greater access to clinical trials and services at SCCs.
尤因肉瘤(EWS)和骨肉瘤(OS)需要多学科治疗。在专门的癌症中心(SCC:儿童肿瘤学组附属和/或美国国家癌症研究所指定的癌症中心)进行治疗已被发现可改善白血病患者的预后,但尚未考虑到 EWS 和 OS 患者的治疗地点和预后,考虑到他们特殊的多学科治疗需求,这是一个理想的评估群体。
使用加利福尼亚癌症登记处与住院数据相关联,确定了 2000-2014 年期间因原发性 EWS 和 OS 住院的患者。患者分为年龄组(0-18 岁、19-39 岁、≥40 岁),并根据他们在诊断后 1 年内是否在 SCC 接受了全部与部分/无 inpatient 治疗进行分类。多变量 Cox 比例风险回归确定了与生存相关的因素。
共有 531 例 EWS 和 959 例 OS 患者。接受 SCC 全部治疗的 EWS(全部:63% vs. 部分/无:42%)和 OS(全部:64% vs. 部分/无:47%)患者的 5 年总生存率更高。在调整了社会人口统计学和临床因素后,在 SCC 接受全部住院癌症治疗与总体生存率的提高相关(EWS HR:0.49,CI 0.37-0.67;OS HR:0.78,CI 0.63-0.97)。
即使在调整了已知的预后因素后,我们的研究结果表明,在 SCC 进行 EWS 和 OS 的治疗与生存率的显著提高相关。在 SCC 治疗的患者中,生存率较高可能是由于在 SCC 更容易获得临床试验和服务。